SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-312030
Filing Date
2022-12-27
Accepted
2022-12-27 06:42:03
Documents
17
Period of Report
2022-12-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d420223d8k.htm   iXBRL 8-K 30269
2 EX-4.1 d420223dex41.htm EX-4.1 61111
3 EX-5.1 d420223dex51.htm EX-5.1 17650
4 EX-10.1 d420223dex101.htm EX-10.1 81919
8 GRAPHIC g420223555_capture.jpg GRAPHIC 9705
9 GRAPHIC g420223fen_capture.jpg GRAPHIC 9913
  Complete submission text file 0001193125-22-312030.txt   381998

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA kalv-20221223.xsd EX-101.SCH 2854
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20221223_lab.xml EX-101.LAB 17995
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20221223_pre.xml EX-101.PRE 11264
11 EXTRACTED XBRL INSTANCE DOCUMENT d420223d8k_htm.xml XML 3362
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 221486778
SIC: 2834 Pharmaceutical Preparations